Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Cooling for Pain in NF1 Treatment
NCT06132165Phase 1Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Mar 2024
- Primary completion
- Jul 2025
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in neurofibromatosis type 1 (NF1) (4 arms), sponsored by Massachusetts General Hospital. Primary endpoint: Incidence of Treatment-Emergent Adverse Events at 3 months. Started Mar 2024; status: completed.
02
Conditions
neurofibromatosis type 1 (NF1)
Beyond the preview
Go deeper on NCT06132165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06132165.